Sensus Healthcare (NASDAQ:SRTS) Director Eric Sachetta Buys 9,708 Shares of Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta acquired 9,708 shares of Sensus Healthcare stock in a transaction that occurred on Wednesday, August 26th. The stock was purchased at an average price of $3.29 per share, with a total value of $31,939.32. Following the transaction, the director owned 219,018 shares of the company’s stock, valued at $720,569.22. This trade represents a 4.64% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Eric Sachetta also recently made the following trade(s):

• On Thursday, August 27th, Eric Sachetta bought 10,925 shares of Sensus Healthcare stock. The shares were acquired at an average price of $3.18 per share, for a total transaction of $34,741.50.
• On Monday, August 24th, Eric Sachetta bought 34,697 shares of Sensus Healthcare stock. The shares were acquired at an average cost of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Trading Up 3.9%

Shares of SRTS traded up $0.13 during mid-day trading on Friday, hitting $3.50. The company’s stock had a trading volume of 62,187 shares, compared to its average volume of 64,747. The firm has a 50-day simple moving average of $3.04 and a 200 day simple moving average of $3.52. The firm has a market capitalization of $57.61 million, a P/E ratio of -3.72 and a beta of 1.10. Sensus Healthcare, Inc. has a 1-year low of $2.66 and a 1-year high of $5.49.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million. Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.

Wall Street Analysts Forecast Growth

SRTS has been the subject of a number of research analyst reports. Weiss Ratings downgraded shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Lake Street Capital decreased their price objective on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Finally, Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $5.83.

Institutional Investors Weigh In On Sensus Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in the business. EP Wealth Advisors LLC acquired a new stake in Sensus Healthcare in the 2nd quarter valued at about $49,000. XTX Topco Ltd acquired a new position in Sensus Healthcare during the fourth quarter worth about $77,000. Jane Street Group LLC acquired a new position in Sensus Healthcare during the fourth quarter worth about $79,000. Ingalls & Snyder LLC purchased a new stake in shares of Sensus Healthcare in the fourth quarter valued at about $219,000. Finally, State Street Corp grew its position in shares of Sensus Healthcare by 5.2% in the fourth quarter. State Street Corp now owns 69,252 shares of the company’s stock valued at $276,000 after purchasing an additional 3,400 shares during the last quarter. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.